Adeno-Associated Virus Serotypes 1, 8, and 9 Share Conserved Mechanisms for Anterograde and Retrograde Axonal Transport
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Adeno-associated virus (AAV) vectors often undergo long-distance axonal transport after brain injection. This leads to transduction of brain regions distal to the injection site, although the extent of axonal transport and distal transduction varies widely among AAV serotypes. The mechanisms driving this variability are poorly understood. This is a critical problem for applications that require focal gene expression within a specific brain region, and also impedes the utilization of vector transport for applications requiring widespread delivery of transgene to the brain. Here, we compared AAV serotypes 1 and 9, which frequently demonstrate distal transduction, with serotype 8, which rarely spreads beyond the injection site. To examine directional AAV transport in vitro, we used a microfluidic chamber to apply dye-labeled AAV to the axon termini or to the cell bodies of primary rat embryonic cortical neurons. All three serotypes were actively transported along axons, with transport characterized by high velocities and prolonged runs in both the anterograde and retrograde directions. Coinfection with pairs of serotypes indicated that AAV1, 8, and 9 share the same intracellular compartments for axonal transport. In vivo, both AAV8 and 9 demonstrated anterograde and retrograde transport within a nonreciprocal circuit after injection into adult mouse brain, with highly similar distributions of distal transduction. However, in mass-cultured neurons, we found that AAV1 was more frequently transported than AAV8 or 9, and that the frequency of AAV9 transport could be enhanced by increasing receptor availability. Thus, while these serotypes share conserved mechanisms for axonal transport both in vitro and in vivo, the frequency of transport can vary among serotypes, and axonal transport can be markedly increased by enhancing vector uptake. This suggests that variability in distal transduction in vivo likely results from differential uptake at the plasma membrane, rather than fundamental differences in transport mechanisms among AAV serotypes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456 · cited 1×
“…2006), diffusely transduce large brain volumes via intraventricular (Passini et al. , 2003; Karolewski and Wolfe, 2006; Cearley et al. , 2008) or intravenous administration (Foust et al. , 2009; Gray et al. , 2011), or transfer genes to primary cultures of neurons and glia (Royo et al. , 2008).”
Burger, C., Gorbatyuk, O. S., Velardo, M. J., Peden, C. S., Williams, P., Zolotukhin, S., Reier, P. J., Mandel, R. J., & Muzyczka, N. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.05.024 · Cited by 741
Davidson, B. L., Stein, C. S., Heth, J. A., Martins, I., Kotin, R. M., Derksen, T. A., Zabner, J., Ghodsi, A., & Chiorini, J. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3428 · Cited by 531 · cited 8×
“CMV.eGFP or AAV2/9.”
InfluentialGray, S. J., Matagne, V., Bachaboina, L., Yadav, S., Ojeda, S. R., & Samulski, R. J. (2011) · Molecular Therapy · doi:10.1038/mt.2011.72 · Cited by 501 · cited 2×
“…2006), diffusely transduce large brain volumes via intraventricular (Passini et al. , 2003; Karolewski and Wolfe, 2006; Cearley et al. , 2008) or intravenous administration (Foust et al. , 2009; Gray et al. , 2011), or transfer genes to primary cultures of neurons and glia (Royo et al. , 2008).”
New recombinant serotypes of AAV vectors
Gao, G., Vandenberghe, L., & Wilson, J. (2005) · Current Gene Therapy · doi:10.2174/1566523054065057 · Cited by 487
Comparative Analysis of Adeno-Associated Viral Vector Serotypes 1, 2, 5, 7, And 8 in Mouse Brain
Taymans, J.-M., Vandenberghe, L. H., Haute, C. V. D., Thiry, I., Deroose, C. M., Mortelmans, L., Wilson, J. M., Debyser, Z., & Baekelandt, V. (2007) · Human Gene Therapy · doi:10.1089/hum.2006.178 · Cited by 305 · cited 22×
“…ISH, in situ hybridization. substantial differences in axonal transport and distribution of gene transfer among serotypes in vivo (Burger et al. , 2004; Cearley and Wolfe, 2006, 2007; Klein et al. , 2006, 2008; Li et al. , 2006; Taymans et al. , 2007; Cearley et al. , 2008; Hollis et al. , 2008).”
InfluentialKlein, R. L., Dayton, R. D., Tatom, J. B., Henderson, K. M., & Henning, P. P. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300331 · Cited by 196 · cited 13×
“…ISH, in situ hybridization. substantial differences in axonal transport and distribution of gene transfer among serotypes in vivo (Burger et al. , 2004; Cearley and Wolfe, 2006, 2007; Klein et al. , 2006, 2008; Li et al. , 2006; Taymans et al. , 2007; Cearley et al. , 2008; Hollis et al. , 2008).”
InfluentialThe AAV9 receptor and its modification to improve in vivo lung gene transfer in mice
Bell, C. L., Vandenberghe, L. H., Bell, P., Limberis, M. P., Gao, G.-P., Van Vliet, K., Agbandje-McKenna, M., & Wilson, J. M. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57367 · Cited by 190 · cited 5×
“These serotypes have unique immune profiles (Gao et al. , 2005), and each utilizes a different primary receptor for uptake (Akache et al. , 2006; Wu et al. , 2006; Bell et al. , 2011; Shen et al. , 2011).”
InfluentialExpanded Repertoire of AAV Vector Serotypes Mediate Unique Patterns of Transduction in Mouse Brain
Cearley, C. N., Vandenberghe, L. H., Parente, M. K., Carnish, E. R., Wilson, J. M., & Wolfe, J. H. (2008) · Molecular Therapy · doi:10.1038/mt.2008.166 · Cited by 182 · cited 20×
“…ISH, in situ hybridization. substantial differences in axonal transport and distribution of gene transfer among serotypes in vivo (Burger et al. , 2004; Cearley and Wolfe, 2006, 2007; Klein et al. , 2006, 2008; Li et al. , 2006; Taymans et al. , 2007; Cearley et al. , 2008; Hollis et al. , 2008).”
InfluentialSelf-citationSondhi, D., Hackett, N. R., Peterson, D. A., Stratton, J., Baad, M., Travis, K. M., Wilson, J. M., & Crystal, R. G. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300049 · Cited by 170 · cited 5×
“…the probability of distal transduction can be reduced by injecting a smaller amount of vector, or by using a serotype with weak CNS tropism such as AAV2 (Davidson et al. , 2000; Burger et al. , 2004; Klein et al. , 2006; Reimsnider et al. , 2007; Sondhi et al. , 2007; Taymans et al. , 2007).”
Influential
Cited by
A Designer AAV Variant Permits Efficient Retrograde Access to Projection Neurons
Tervo, D. G. R., Hwang, B.-Y., Viswanathan, S., Gaj, T., Lavzin, M., Ritola, K. D., Lindo, S., Michael, S., Kuleshova, E., Ojala, D., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.09.021 · Cited by 1,179
Zingg, B., Chou, X.-L., Zhang, Z.-G., Mesik, L., Liang, F., Tao, H. W., & Zhang, L. I. (2017) · Neuron · doi:10.1016/j.neuron.2016.11.045 · Cited by 752
Therapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality
Hudry, E., & Vandenberghe, L. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.017 · Cited by 369
Gene therapy for neurological disorders: progress and prospects
Deverman, B. E., Ravina, B. M., Bankiewicz, K. S., Paul, S. M., & Sah, D. W. Y. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.110 · Cited by 306
Viral Strategies for Targeting the Central and Peripheral Nervous Systems
Bedbrook, C. N., Deverman, B. E., & Gradinaru, V. (2018) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-080317-062048 · Cited by 168
Controlling AAV Tropism in the Nervous System with Natural and Engineered Capsids
Castle, M. J., Turunen, H. T., Vandenberghe, L. H., & Wolfe, J. H. (2016) · Methods in Molecular Biology · doi:10.1007/978-1-4939-3271-9_10 · Cited by 151
“Within the brain, AAV9 is most frequently observed to undergo axonal transport, and is the recommended choice if distal transduction is desired [21, 23, 34, 36, 57, 60].”
BackgroundSelf-citationSaunders, A., Huang, K. W., & Sabatini, B. L. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149798 · Cited by 109
Seitz, I. P., Michalakis, S., Wilhelm, B., Reichel, F. F., Ochakovski, G. A., Zrenner, E., Ueffing, M., Biel, M., Wissinger, B., Bartz-Schmidt, K. U., et al. (2017) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.17-22473 · Cited by 108
“Our data are in line with these reports and show that dose and route of application are important determinants of the extent of this distribution pattern.(27) While our data do not explain the mechanism of transduction along the visual pathway, they clearly show that both routes of application can lead to anterograde…”
Alhadeff, A. L., Mergler, B. D., Zimmer, D. J., Turner, C. A., Reiner, D. J., Schmidt, H. D., Grill, H. J., & Hayes, M. R. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.246 · Cited by 102
“Importantly, as AAV-1 serotypes are able to be transported to neuronal processes (Castle et al, 2014), we cannot rule out the possible contribution of GLP-1R knockdown in distal CNS nuclei innervated by NTS neurons.”
BackgroundGlymphatic fluid transport controls paravascular clearance of AAV vectors from the brain
Murlidharan, G., Crowther, A., Reardon, R. A., Song, J., & Asokan, A. (2016) · JCI Insight · doi:10.1172/jci.insight.88034 · Cited by 72
Intramuscular Delivery of Gene Therapy for Targeting the Nervous System
Tosolini, A. P., & Sleigh, J. N. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00129 · Cited by 32
Improving gene therapy for Angelman syndrome with secreted human UBE3A
Nenninger, A. W., Willman, M., Willman, J., Stewart, E., Mesidor, P., Novoa, M., Morrill, N. K., Alvarez, L., Joly-Amado, A., Peters, M. M., et al. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01239-2 · Cited by 15
Han, G., Zhang, B., Zhang, H., Han, D., Tan, J., & Yang, B. (2019) · Journal of Materials Science: Materials in Medicine · doi:10.1007/s10856-018-6209-3 · Cited by 11
Metadata
- Authors
- Castle, M. J., Gershenson, Z. T., Giles, A. R., Holzbaur, E. L. F., & Wolfe, J. H.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2014-08
- Volume
- 25
- Issue
- 8
- Pages
- 705-720
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W2023095885
- Cited by
- 154
- References
- 12
- FWCI
- 7.73
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.